[BeOne Medicines Ltd.] BeOne Medicines Ltd. announced that the Us FDA has accepted and granted Priority Review to the supplemental New Drug Application for BRUKINSA^® (zanubrutinib) in combination with rituximab for the treatment of adult patients with previously untreated mantle cell lymphoma.

[City of Hope^®] Researchers at City of Hope^® and collaborators have pioneered a new approach to preventing dangerous bloodstream infections in patients receiving donor stem cell transplants for blood cancers.

[Starton Therapeutics Inc.] Starton Therapeutics Inc. announced that it has signed a clinical trial agreement with the Stanford School of Medicine to evaluate Starton’s lead candidate STAR-lenalidomide (LLD), in combination with a novel CAR-T cell therapy, for the treatment of multiple myeloma.

[Pfizer Inc.] Pfizer Inc. announced topline results from the Phase III MagnetisMM-32 study evaluating ELREXFIO^® (elranatamab) as monotherapy in adults with relapsed or refractory multiple myeloma who received at least one prior line of treatment with anti-CD38 therapy and lenalidomide.

[Science Advances] Using human AML cells and murine models, the authors identify BCL2-associated transcription factor 1 (BCLAF1) as a key regulator of leukemic progression through control of mRNA processing.

[Cancer Research] Investigators developed and evaluated PinA1, a molecular glue degrader targeting CK1α, in preclinical AML models.

[Cancer Research] Scientists explored the chronic myeloid leukemia-specific information content encoded in single-cell RNA-sequencing versus bulk transcriptomics to resolve this paradox and clarify how discrete disease-defining states emerge from inherently noisy single-cell data.

[American Journal of Hematology] Researchers analyzed 11 340 patients and identified 418 BCOR/L1-mutated patients, focusing on differences between myeloid neoplasms and bone marrow failure syndromes.

[Nature Cardiovascular Research] The authors performed multiomics profiling and functional characterization of mouse models and patient-derived data to show that hematopoietic KDM6A loss impairs cardiac recovery after myocardial infarction.

[Cell Reports] Investigators built a comprehensive atlas of leukemia and its microenvironment by integrating single-cell profiling from AML samples and healthy donors, bulk RNA sequencing from newly diagnosed patients, and paired bone marrow and peripheral blood single-cell data.

[Nature Genetics] Researchers studied patients with lymphoma receiving CD19-directed chimeric antigen receptor T cell therapy (CAR19) and compared clinical outcomes to propensity-matched autologous hematopoietic cell transplantation-treated controls.

[British Journal of Haematology] Scientists investigated the association between fetal hemoglobin and treatment outcome in the randomized phase III European Organization for Research and Treatment of Cancer (EORTC)-1301 trial AML21.